BioCryst Pharmaceuticals, Inc.

NASDAQ: BCRX
$1.99
+$0.08 (+4.2%)
Closing price March 30, 2020
As with almost all pandemic scares and other national and global issues, some speculative stocks manage to see their shares rise sharply.
Chris Lange
The Wuhan Coronavirus has escaped China, with the number of cases and the death toll rising. The economic impact beyond the loss of life and suffering is real in many stocks, sectors and local...
Jon C. Ogg
The Wuhan Coronavirus has already left China and hit neighboring countries, the U.S. and even in Europe in Australia. As the death toll and number of infected are rising each hour, the economic...
Jon C. Ogg
BioCryst Pharmaceuticals shares were absolutely crushed in Tuesday’s session after the company announced late-stage results for its study in hereditary angioedema patients.
Chris Lange
Every week we search for stocks covered by top Wall Street analysts that are trading under the $10 level and could provide solid upside potential. This week we found five companies covered by...
Lee Jackson
Here are five biotech stocks that are rated Buy by the Jefferies analysts, are trading under the $10 level and could provide investors with some solid upside potential.
Lee Jackson
BioCryst Pharmaceuticals shares fell on Tuesday after the company announced initial results from its hereditary angioedema trial.
Chris Lange
The top analyst upgrades, downgrades and other research calls from Tuesday include Applied Materials, BioCryst, Costco, Generac, Goodyear, Intel, Microsoft and Netflix.
Jon C. Ogg
Idera Pharmaceuticals shares crumbled on Wednesday after BioCryst Pharmaceuticals announced that it terminated the merger agreement.
Chris Lange
The top analyst upgrades, downgrades and other research calls from Friday include Bookings Holdings, Dollar General, KLA-Tencor, Micron Technology, Nike and Red Hat.
Lee Jackson
The top analyst upgrades, downgrades and other research calls from Tuesday include Abbott Labs, Delphi, Lululemon, Netflix, Nordstrom, Sirius XM, Disney and Windstream.
Jon C. Ogg
BioCryst Pharmaceuticals has received an update from the FDA. This approval is very welcome as BioCryst has been underperforming the market so far this year.
Chris Lange
BioCryst Pharmaceuticals watched its shares fall handily on Tuesday after the firm announced a secondary offering.
Chris Lange
The include BioCryst Pharmaceuticals, Exxon Mobil, Fiat Chrysler Automobiles, Hewlett Packard Enterprise, IAMGOLD, Mallinckrodt and Rockwell Collins.
Jon C. Ogg
BioCryst Pharmaceuticals saw its shares make a handy gain on early Tuesday after it released the final results from its mid-stage clinical trial in hereditary angioedema.
Chris Lange